

Index

Notes

ASRM = American Society for Reproductive Medicine
ESHRE = European Society of Human Reproduction and Embryology
FSH = follicle-stimulating hormone
hCG = human chorionic gonadotrophin
HDL = high-density lipoprotein
hMG = human menopausal gonadotrophin
HRQoL = health-related quality of life
IDF = International Diabetes Federation

IVF = *in vitro* fertilisation
IVM = *in vitro* maturation of oocytes
NICE = National Institute for Health and Clinical Excellence
OHSS = ovarian hyperstimulation syndrome
PCOS = polycystic ovary syndrome
RCT = randomised controlled trial
SHBG = sex hormone-binding globulin
WHO = World Health Organization

abnormal glucose tolerance (AGT) 33, 36, 38
acanthosis nigricans 33, 75
acarbose 137
acne 126–33
 in adolescence 74
 ethnic variations 38
 hormonal influences causing 127
 in/due to hyperandrogenism 74, 117, 118, 125, 126
 scoring, recommendation 122
 nodular lesions, treatment 128
 pathophysiology 126–7
 treatment 214
 algorithm 126
 alternative therapies/procedures 128–9
 androgen receptor blockers 132–3
 general advice 127
 hormonal therapy 130–3
 metformin 133
 mild/moderate inflammatory lesions 128
 non-inflammatory lesions 128, 129
 skincare and cosmetics 129
 by sub-type 126, 127–8
 systemic therapies 129–33
 see also antiandrogens
acupuncture in PCOS 195
 action mechanisms in PCOS 198–200
 auricular 202
 evidence for use 200–4
 mental health, effects 203–4
 metabolic abnormalities, effects 202–3
 ovulation, effects 200–2
 sympathetic nervous system, effects 204
 needle placement 200
 physiological basis 195, 196–8
 spinal and central mechanisms 197
 trials 201, 203
 continuing or completed RCTs 205
 standards and reporting 207

see also electro-acupuncture (EA)
adapalene 128
adhesions, periovarian 166, 167
adipocytes 96
adipokines 65
adipose tissue
 inflammatory cytokine synthesis 65
 insulin resistance 106
 pathophysiology of PCOS 95, 96
adolescents, PCOS in
 age of PCOS manifestation 6, 14, 71
 clinical evaluation 78
 clinical features 73–4
 depression 74
 diagnosis 71–4, 78
 differential diagnosis 75
 hormonal changes 73, 95
 HRQoL 52, 54, 57
 impact of PCOS-associated obesity 53
 infertility concerns 55
 investigations 78
 management 71–83
 menstrual cycle 72–3
 moderate/severe, quality of life 54
 monitoring 79
 ovarian appearance on ultrasound 72–3
 overweight 53, 74, 95
 recommendations 78–9
 treatment 75–8
 antiandrogens 77–8
 effect on quality of life 74
 metformin 76–7, 78–9
 oral contraceptive pills 75–6, 78
 recommendations 78–9
 thiazolidinediones 77
 weight loss 75
 see also puberty
adrenal gland, PCOS development 15
adrenoceptors 204
adrenocorticotrophic hormone (ACTH) 198

Cambridge University Press

978-1-906-98541-7 - Current Management of Polycystic Ovary Syndrome

Edited by Adam Balen, Stephen Franks, Roy Homburg and Sean Kehoe

Index

[More information](#)

218 | INDEX

- aetiology of PCOS 198
 - developmental 14–16, 74–5, 95
 - ethnic factors 26
 - genetic factors *see* genetics of PCOS
 - neuroendocrine defects 198
- African-American women, PCOS 34
- age of onset 6, 14, 71
 - Asian women 32
 - non-Asian women 34
- age of woman, prediction of response to FSH 158, 159
- alopecia, androgenic 74
 - in hyperandrogenism 117, 119, 122, 125
 - treatment 137–8, 214
- American Society for Reproductive Medicine (ASRM) 1, 13, 94, 213
 - PCOS diagnostic criteria 117
- anastrozole 146, 147
- androgen(s)
 - clearance, ethnic variations 38
 - excess production 14, 125, 127
 - acne and hirsutism due to 74, 117, 118, 125, 126
 - cyproterone acetate treatment 76
 - effects 125
 - fetal ovary 15, 95
 - insulin resistance development 38
 - see also* hyperandrogenism/hyperandrogenaemia
 - inhibition of production *see* antiandrogens
 - raised, definition 120
 - receptor blockers 77–8
 - acne treatment 132–3
 - hirsutism treatment 135–6
 - see also* finasteride; flutamide; spironolactone
 - receptors 96, 125
 - reference limits 120, 121
 - synthesis 15, 65
 - see also* testosterone
- Androgen Excess and PCOS Society (AEPS) 4, 117
- androgenic alopecia *see* alopecia, androgenic
- androgenisation, premature 95
- androstenedione 5, 71, 120, 126
- Δ4-androstenedione 96
- aneuploidy 191
- animal models 95
- anovulation 4, 13, 47, 154
 - assessment 120, 122
 - endometrial hyperplasia and 89, 214
 - hypogonadism 9
 - IVM *see in vitro* maturation of oocytes (IVM)
 - mechanism 143
 - surgical management *see* surgical management
 - treatment 143–52
 - acupuncture 200–2
 - algorithm 155
 - aromatase inhibitors 145–7
 - clomifene citrate 144–5, 154, 214
 - herbal therapy 205–6
 - individualised treatment 153, 161
 - low-dose gonadotrophins 148–50, 157–60
 - metformin *see* metformin
 - outcomes 155
 - predictors of response *see* ovarian response
 - weight loss 100, 105–6, 143
 - see also* infertility
- antiandrogens 77–8
 - acne treatment 129–33
 - adrenal androgen production inhibition 129–30
 - in androgenic alopecia 137
 - in hirsutism 135–6
 - ovarian androgen production inhibition 130–2
 - GnRH agonists 132
 - oral contraceptives 130–2
 - PCOS treatment in adolescence 77–8
 - see also* androgen(s), receptor blockers
- anti-estrogen therapy
 - ovulation induction by 154
 - response prediction 154–7
 - integrated double nomogram 156, 157
 - see also* clomifene citrate
- antiMüllerian hormone (AMH)
 - gene polymorphism 161
 - normal range 3
 - puberty/adolescence 73
- anti-obesity drugs 99, 106–9
 - see also* orlistat; sibutramine
- anxiety 52
- Arab women, PCOS 31, 35
- aromatase gene 161
- aromatase inhibitors 145–7
- Asian women
 - age of onset of PCOS 32
 - obesity, insulin resistance, metabolic syndrome 32–4
 - see also* South Asian people
- assisted reproductive technology (ART) 186
 - see also in vitro* fertilisation (IVF); *in vitro* maturation of oocytes (IVM)
- atherosclerosis, subclinical, markers 86
- atorvastatin 68
- bariatric surgery 99, 109–12, 214
 - conception timing after 112
 - effects on PCOS 110–11
 - NICE recommendation 110
 - nutritional deficiencies after 112
 - pregnancy after 110, 111–12
 - procedures 109–10
 - weight loss with 109

- berberine 206
- biguanides 173
 - see also* metformin
- biliopancreatic diversion 110, 111
- biochemical changes 3, 4, 16
 - in puberty/adolescence 73
- birth rate *see* live birth rate
- blood pressure, systolic
 - metabolic syndrome 87
 - sibutramine increasing 108
- body image, poor 53
- body mass index (BMI) 14, 94
 - bariatric surgery recommendation 110, 214
 - impact on quality of life 53, 54
 - metformin effect 180
 - non-Asian women 34
 - orlistat effect 107
 - prediction of response to anti-estrogens 154
 - sibutramine effect 107–8
 - South Asian women 33, 34
 - weight loss in obesity 106
- breast cancer 89
- bypass procedures, bariatric surgery 110, 111
- carbohydrate restriction 67
- cardiovascular disease
 - markers/surrogates 86–7
 - in mothers of women with PCOS 67
 - PCOS as marker 66, 87–8
 - recommendations for screening/treatment 88
 - risk with PCOS 85–8
 - metabolic syndrome and 86–7
- cardiovascular risk factors 66, 86
 - management 88
 - obesity 105
 - in South Asian women 33
- Caribbean Hispanic women, PCOS 27, 28
- Child Health Questionnaire Version CF-87 (CHQ-CF87) 51
- children, obesity and overweight
 - PCOS prevalence 18
 - type 2 diabetes and 26
- Chinese women, PCOS 33, 35, 37
- D-chiro-inositol 173
- chromosome abnormalities 191
- cinnamon 206
- clinical features *see* symptoms/signs of PCOS
- clomifene citrate 144–5, 214
 - actions, dose and results 144
 - adjuvant therapy 145
 - body mass index changes 180
 - metformin action compared 148, 175
 - metformin with 175
 - multiple pregnancy rates 176–7
 - prediction of response to 154–7
 - resistance 144, 147, 155, 157, 168
 - laparoscopic ovarian diathermy 168, 169
 - low-dose step-up FSH therapy 149–50
 - treatment failure 144, 157, 159
 - gonadotrophin use in 157, 159
 - treatment outcomes 155, 156
- co-cyprindiol 130
 - acne treatment 130–1
 - venous thromboembolism risk 131
 - see also* cyproterone acetate
- cognitive behavioural therapy, in obese adolescents 74
- combined oral contraceptives (COCs) *see* oral contraceptive pills
- comedo extraction 129
- comedones, closed 127–8
- conception
 - prediction, after anti-estrogens 155, 157
 - timing after bariatric surgery 112
- congenital abnormalities *see* malformations
- congenital adrenal hyperplasia 8, 125, 129
- consensus views (59th Study Group) 213–15
 - diagnosis and pathophysiology 213
 - management 213–14
 - research 214–15
- corticotrophin-releasing factor (CRF) 198
- cortisol 198
- cosmetic approaches, hirsutism management 134
- counselling, preconception 133, 213
- C-reactive protein (CRP) 68, 86
- CYP11A locus 17
- cyproterone acetate 76, 78
 - acne treatment 130–1
 - actions 130
 - adverse effects 131
 - hirsutism management 135
 - see also* co-cyprindiol
- cytokines, synthesis by adipose tissue 65
- definitions of PCOS 1–12, 117
 - see also* Rotterdam criteria
- dehydroepiandrosterone (DHEA) 74, 126
- dehydroepiandrosterone sulfate (DHEAS) 73, 74, 120, 127
- depression 52, 89, 196
 - acupuncture effects 203–4
 - adolescents 74
 - laser treatment of hirsutism effect 56
- desogestrel 76
- developmental origins of PCOS 14–16, 74–5, 95
- dexamethasone 129, 145
- diabetes
 - blood glucose levels 3
 - gestational, polycystic ovaries prevalence 66
 - PCOS as prediabetic state 66
 - prevention, metformin effect 179–80, 214

Cambridge University Press

978-1-906-98541-7 - Current Management of Polycystic Ovary Syndrome

Edited by Adam Balen, Stephen Franks, Roy Homburg and Sean Kehoe

Index

[More information](#)

220 | INDEX

- diabetes (*cont.*)
 type 2
 in Asian women 32
 development 97
 herbal therapy effects 206
 metabolic syndrome progression
 prevention 68
 obesity impact on prevalence 88
 overweight/obese girls 18–19, 26
 PCOS as marker 65–6
 prevalence in PCOS 65–6, 88
 risk with PCOS 88–9
 rural and urban India 38
- Diabetes Prevention Program 179, 180
- diagnosis of PCOS 5, 9, 63
 adolescence 71–4, 78
 criteria 117
 ethnic differences in thresholds for 39
 by exclusion 8–9, 75
 historical aspects 5–6
 as indicator of cardiovascular risk 88
see also Rotterdam criteria
- dienogest 131
- diet
 macronutrient composition 99
 sibutramine with, trial 108
 very low calorie 106
- dietary approaches
 obesity treatment 98
 PCOS treatment 67
- differential diagnosis of PCOS, adolescents 75
- 5 α -dihydrotestosterone (DHT) 202
- Doppler ultrasound 8
- drospirenone 76, 79
 acne treatment 131
 hirsutism management 135
- duodenal switch–biliopancreatic division 110
- dutasteride 137
- East Asian women, hyperandrogenism 35, 37
- Eastern European groups, PCOS 31
- eating disorders 53, 196
- echogenicity, stromal 7
- eflornithine hydrochloride 134–5
- electro-acupuncture (EA) 196
 low-frequency 196, 202, 203
 metabolic abnormalities, effects 203
 ovulation, effects 202
 sympathetic nervous system, effects 204
 neuropeptides released 197–8
 physiological effects 196, 197–8
see also acupuncture
- electrocautery, laparoscopic *see* laparoscopic electrocautery
- electrolysis, hirsutism management 134
- embryo culture, prolonged 185
- Endocrine Society 119, 120
- endometrial carcinoma 89, 180, 214
- endometrial hyperplasia 89, 180, 214
- endometrial priming, for IVM 187, 189
- endometrial thickness, clomifene citrate effect 145
- β -endorphin 197–8, 199
 pathogenesis of PCOS 198, 199
- endothelial dysfunction 38, 86
- endothelin I 86
- energy restriction 98, 99
- environmental factors 18–19
- epidemiology of PCOS
 diabetes prevalence in 65–6, 88
 ethnic variations *see* ethnic variations
 impaired glucose tolerance prevalence in 14, 65
 insulin resistance prevalence in 38–9
 prevalence of PCOS 4, 13, 38–9, 47
- estradiol, normal range 3
- estradiol valerate 187, 204
- estrogen
 biosynthesis, suppression by aromatase inhibitors 145
 glucocorticoids with, acne treatment 129–30
 in oral contraceptives, acne treatment 130
 priming, *in vitro* maturation (IVM) 187
- ethinylestradiol
 acne management 130, 131, 132
 hirsutism management 135
- ethnicity 25–6
 continental basis, criticisms 26
- ethnic variations, of PCOS expression 25–45
 Arab, Mediterranean and European women 27, 31, 35
 diagnostic threshold differences 39
 evidence for 27
 Far East Asian groups 30–1
 historical background 27
 hyperandrogenism 35–7
 East Asian women 35, 36, 37
 metabolic problems relationship 37–8
 multi-ethnic groups outside USA 28–9
 obesity, insulin resistance, metabolic syndrome 32–5, 36
 Asian women 32–4
 insulin resistance variations 38–9
 non-Asian women 34–5
 PCOS prevalence 40
 psychological distress 52
 quality of life in PCOS 39
 US-based multi-ethnic groups 30
- euglycaemic hyperinsulinaemic clamp 64
- European Society of Human Reproduction and Embryology (ESHRE) 1, 13, 93–4, 213
 PCOS diagnostic criteria 117
- European women, PCOS 27, 31, 35
- exercise 98, 204

- facial hirsutism, laser treatment, HRQoL after 56
- family members, PCOS implications 67
- fat, subcutaneous, insulin resistance and 106
- fatty liver disease, non-alcoholic 66–7
- female–pattern hair loss *see* alopecia, androgenic
- Ferriman–Gallwey system 118, 119, 179
- fertilisation rates, IVF *vs* IVM 190
- fertility problems 1
 - see also* infertility
- fetal ovary, PCOS development 15, 18, 95
- fibrillin 3 gene (*FBN3*) 17
- finasteride
 - acne treatment 133
 - androgenic alopecia treatment 137
 - hirsutism treatment 136
- flutamide 77–8, 79
 - acne treatment 132–3
 - hepatotoxicity 133, 136
 - hirsutism treatment 136
- follicle(s)
 - antral, count, *in vitro* maturation (IVM) 186
 - diameter, timing of immature oocyte retrieval 189
 - growth, FSH regulation 157
 - increase in number 5
 - primordial 5–6
- follicle number per ovary (FNPO) 6–7
- follicle-stimulating hormone (FSH)
 - discharge, aromatase inhibitor effect 146
 - dose threshold 158, 159, 160, 161
 - low-dose, anovulation treatment 148
 - low-dose step-down protocol 149
 - low-dose step-up protocol 149, 150
 - normal range 3
 - in PCOS 5, 13
 - prediction of response to 154, 158–60
 - priming, *in vitro* maturation (IVM) 188
 - recombinant (rFSH) 168
 - impact on HRQoL 55–6
 - regulation 157
- follicle-stimulating hormone receptor (*FSHR*)
 - gene 161
- free androgen index (FAI) 120
 - calculation 87, 120
 - as cardiovascular risk factor 87
 - normal range 3
 - prediction of response to anti-estrogens 154
 - prediction of response to FSH 159
- free fatty acids (FFAs) 96, 106
- FSH *see* follicle-stimulating hormone (FSH)
- FTO* (fat mass and obesity-associated) gene 17
 - effects on PCOS 110–11
- genetic differentiation, ethnic groups 26
- genetics of PCOS 16–17, 27, 67
 - candidate genes 17, 67
 - predictors of ovarian response 161–2
- genome-wide association studies 17, 19
- Global Alliance to Improve Outcomes in Acne 133
- glucocorticoids, acne treatment 129
- glucose tolerance 3
 - abnormal 33, 36, 38
 - impaired *see* impaired glucose tolerance (IGT)
- glucose tolerance test, oral 78
- glucose transporter 4 (*GLUT4*) 64, 96, 203
- gonadotrophin(s) 157
 - anovulation therapy 148–50, 157–60
 - in vitro* maturation of oocytes (IVM) 188
 - in OHSS prevention 186
 - prediction of ovarian response to 157–60
 - outcomes 158, 159, 160
 - see also* follicle-stimulating hormone (FSH); luteinising hormone (LH)
- gonadotrophin-releasing hormone (GnRH)
 - agonists 132, 136
- gonadotrophin-releasing hormone (GnRH)
 - pulse generator 198
- gynaecological malignancies 89
- hair follicles, excess androgen effect 125
- hair-growth scores, standardisation 118–19
- hair thinning 74
 - see also* alopecia, androgenic
- health-related quality of life (HRQoL) 47
 - of adolescents 52, 54, 57
 - body mass index impact 53, 54
 - definition 48, 58
 - impact of PCOS 51, 52, 57, 58
 - impact of PCOS-associated infertility 54–5, 58
 - impact of PCOS-associated obesity 52–4
 - impact of PCOS-associated sexual functioning 55
 - impact of PCOS treatment 55–7, 58
 - key areas 49
 - measurement 48–9, 57, 58
 - condition-specific questionnaire 48
 - disease-specific questionnaire 48, 58
 - generic questionnaires 48, 50–1, 58
 - PCOSQ 49, 50, 57
 - reliability 49
 - types of instrument for 49–50
 - validation 49
- herbal therapy 196, 205–6
 - for metabolic abnormalities 206
 - ovulation induction 205–6
- high-density lipoprotein (HDL)
 - cyproterone acetate increasing 76
 - low, metabolic syndrome risk 87
- gastrectomy, sleeve 109
- gastric banding 109, 111
- gastric bypass procedures 110, 111
- gastroplasties 109–10

Cambridge University Press

978-1-906-98541-7 - Current Management of Polycystic Ovary Syndrome

Edited by Adam Balen, Stephen Franks, Roy Homburg and Sean Kehoe

Index

[More information](#)**222 | INDEX**

- high-density lipoprotein (HDL) (*cont.*)
 metabolic syndrome diagnosis 64, 87
 metformin effect on 77
 thresholds (adult and children) 87
 waist circumference and 87
 weight loss-associated increase 106
- hirsutism 18, 35, 96
 in adolescence 74
 diagnosis 118
 ethnic variations 35
 in hyperandrogenism 117, 118, 125, 126, 134–7
 reduction after bariatric surgery 111
 scoring systems 118, 119, 122
 treatment 134–7, 214
 cosmetic/physical approaches 134
 laser, impact on HRQoL 56
 metformin 133, 178–9
 systemic 135–7
 topical 134–5
- Hispanic Americans, PCOS in 27
- histology 5–6
- homeostatic model assessment (HOMA)
 method 107
- homocysteine 38, 86
- hormones
 changes at puberty/adolescence 73, 95
 normal ranges 3
- Hospital Anxiety and Depression Scale (HADS) 52, 56
- human chorionic gonadotrophin (hCG) 202
 administration criteria, low-dose FSH and 148
 clomifene citrate with 145
 priming, IVM protocol 186, 188
- human menopausal gonadotrophin (hMG) 202
- hydrolaparoscopy, transvaginal 169
- 11 β -hydroxydehydrogenase 96
- 17 β -hydroxydehydrogenase 96
- 21-hydroxylase, deficiency 129
- hyperandrogenism/hyperandrogenaemia 1–2, 4, 5, 9, 18, 117–24, 198
 adolescence 95
 anovulation assessment 121, 122
 biochemical, diagnosis 118, 119–21
 choice of androgen for 119, 120
 recommendations 122
 reference limits for androgens 120, 121, 122
 time of blood sampling 120
 as cardiovascular risk factor 87
 clinical 118–19
 recommendations 122
 clinical features 47, 117, 118–19, 125, 126
 see also acne; alopecia, androgenic; hirsutism
 definition 117
 diagnostic criteria proposed 121–2
 ethnic variations 35–7
 East Asians 35, 37
 hyperinsulinaemia relationship 65
 occult form 121
 steroids involved 126
 treatment 125–41, 196
 of acne and hirsutism *see* acne; hirsutism
 mechanisms of action 126
 see also androgen(s), excess production
- hyperglycaemia, metabolic syndrome diagnosis 64, 87
- hyperinsulinaemia 1–2, 4, 9, 13, 18
 hyperandrogenism relationship 65
 laparoscopic ovarian surgery effect 168
 opioid inhibition 199
 in puberty 16, 73
 reduction, hirsutism improvement 136
 SHBG affected by 87
 type 2 diabetes development 88
see also insulin resistance, and PCOS
- hyperkeratinisation, follicular 127
- hyperpigmentation, post-inflammatory 128
- hypoestrogenism 136
- hypogonadism, hypogonadotrophic 9
- hypothalamic–pituitary–ovarian axis 14, 15
 acupuncture effects 202
 β -endorphin effect 198
- Icelandic women, PCOS 35, 37
- imaging *see* ultrasound
- immunoassays, testosterone 120, 121
- impaired glucose tolerance (IGT) 3, 88–9
 development 97
 prevalence in PCOS 14, 65
 type 2 diabetes preceded by 88
- implantation rate, IVF *vs* IVM 190, 191
- imprinting disorders 191
- Indian women, PCOS and 38, 52
- infertility 143
 duration, prediction of response to FSH 158, 159
 early onset obesity and 95
 impact on HRQoL 54–5, 58
 IVM *see in vitro* maturation of oocytes (IVM)
 obesity association 99–100
 treatment
 clomifene *see* clomifene citrate
 lifestyle management 99–100
 metformin *see* metformin
 surgical *see* surgical management
see also anovulation
- inflammation, ovary and 65
- inflammatory lesions, in acne 127, 128
- inflammatory mediators 65
- insulin
 androgen production stimulation 65
 as co-gonadotrophin 63, 65
 fasting levels 3
 prediction of response to anti-estrogens 157

- gonadotrophic action 16
- increased *see* hyperinsulinaemia
- pathogenesis of PCOS and 63
- receptors 64, 75
- resistance *see* insulin resistance, and PCOS
- sensitivity, weight loss effect 106
- signalling pathway defects 64, 96
- insulin-like growth factor I (IGF-I) 65, 106, 159
- insulin-like growth factor-binding protein I (IGFBP-I) 106, 157
- insulin receptor substrate 1 (IRS1) 64
- insulin resistance, and PCOS 4, 14, 18, 26, 63–70
 - acupuncture effect 203
 - in adolescence/puberty 16, 73
 - decrease, orlistat effect 107
 - development 74, 75
 - excess androgens role 38
 - endothelial dysfunction and 38
 - epidemiological variations 38–9
 - ethnic variations 32–5, 36
 - Asian women 32–4
 - non-Asian women 34–5
 - insulin receptor mutations and 75
 - laparoscopic ovarian surgery effect 168
 - measurement 64
 - mechanism 64
 - metformin action in pregnancy 178
 - non-alcoholic fatty liver disease risk 66
 - obesity and 96, 97
 - oral contraceptive pill effects on 75–6
 - outcome of FSH therapy and 160
 - type 2 diabetes development 88
- insulin resistance syndromes 9
- insulin-sensitising drugs 94, 173–83
 - acne treatment 133
 - hirsutism treatment 136–7
 - ovulation induction 147–8
 - see also* metformin
- insulin to glucose ratio, prediction of response to FSH 158
- Interceed 167
- interleukin-6 (IL-6) 203
- International Diabetes Federation (IDF) 86
- intracytoplasmic sperm injection (ICSI) 187, 188–9
- intrauterine environment, role 14, 18
- investigations of PCOS 2–5
 - adolescents 78
- in vitro* fertilisation (IVF) 185
 - complications 185
 - congenital abnormality rates 190
 - laparoscopic ovarian diathermy after 167
 - natural-cycle 186, 189
 - results 185
 - IVM comparison 190, 191
 - standard procedure 185
- in vitro* maturation of oocytes (IVM) 185–93, 186
 - consensus views 214
 - culture medium 187
 - endometrial priming 189
 - gonadotrophin ovarian stimulation 188
 - hCG priming 186, 188
 - IVF results *vs* 190, 191
 - metformin co-treatment 189
 - ‘natural cycle’ 189
 - patient selection 187–8
 - protocol 186–7
 - variations 187–9
 - results 190, 191
 - safety 190–1
 - success rates 188, 190
 - timing of oocyte retrieval 186, 189
- Japanese women, PCOS 27, 28
- jejunio-ileal bypass 110
- Labisia pumila* 206
- lactic acidosis 174
- laparoscopic electrocautery 166
 - impact on HRQoL 55–6
- laparoscopic ovarian diathermy (LOD) 165, 200
 - adhesion formation 166, 167
 - advantages 169, 170
 - after/before IVF 167
 - ‘dose response’ 166
 - endocrine changes after 168
 - energy use and outcome 167
 - failure to respond to 168–9
 - ovarian failure due to 167
 - ovulation induction rate 166
 - pregnancy rates 166, 168, 169
- laparoscopic ovarian drilling *see* laparoscopic ovarian diathermy (LOD)
- laparoscopic ovarian surgery 165
- laparoscopy, second-look 167
- laser photocoagulation 167
- laser treatment, facial hirsutism 134
 - impact on HRQoL 56
- leptin 65, 157, 203, 206
- letrozole 145–6
 - dose and results 146, 147
- LH *see* luteinising hormone (LH)
- lifestyle management 93–103, 196, 213–14
 - effect on quality of life, in adolescents 74
 - of infertility 99–100
 - of obesity 98–9, 105–6
- lipoprotein lipase (LPL) 96
- live birth rate
 - in vitro* fertilisation (IVF) 185
 - IVF *vs* IVM 190
 - metformin effect 176
 - ovulation induction treatment outcome 155, 156, 160
- long-term health risks 85–91
 - see also* cardiovascular disease
- low-density lipoprotein (LDL) 68

224 | INDEX

- luteinising hormone (LH)
 clomifene citrate effect 145
 elevated in PCOS 5, 13, 200
 adolescence 71
 hyperandrogenism diagnosis 121
 insulin amplifying effect 63, 65
 normal range 3
 predictive of PCOS 122
 at puberty, PCOS development 15, 95
 reduced by laparoscopic ovarian surgery 165, 168
- luteinising hormone (LH): follicle-stimulating hormone (FSH) ratio 8, 121, 168
- macrocomedones 128
- magnetic resonance imaging (MRI) 8
- malformations (congenital)
 IVM *vs* IVF 190–1
 metformin and 178
- Mediterranean groups, PCOS 31, 38
- meiotic spindle abnormalities 191
- menarche, age 72
- menorrhagia 54
- menstrual cycle
 in adolescence 72
 irregularities 47
 acupuncture effects 200–2
 adolescence 71, 72, 74
 herbal treatment 205, 206
 obese women with PCOS 97
 see also anovulation
 testosterone level variations during 120
- mental health, and PCOS 52
- Mentha spicata* 206
- metabolic disturbances 196
 acupuncture effects on 202–3
see also hyperinsulinaemia; insulin resistance; obesity
- ‘metabolic surgery’ 109
- metabolic syndrome 63–70
 cardiovascular disease risk 86
 diagnosis 63–4, 87
 IDF criteria 86
 WHO defining criteria 64
 inheritance 67
 markers 67
 frequency in PCOS 87
 metformin effect 68
 ovarian function interactions 65
 PCOS association, ethnic variations 32–5
 Asian people 32–4
 non-Asian women 34–5
 South Asian women 34
 risk
 low HDL cholesterol 87
 rural and urban India 38
 waist circumference 33, 64, 86, 87
 treatment 67–8
- metformin 173–81
 acne treatment 133
 adverse effects 79, 173–4
 body mass index changes 180
 Cochrane analysis 180–1
 consensus views 214
 continuation during pregnancy 178
 diabetes prevention 179–80, 181
 dose 174
 endometrial carcinoma prevention 180
 hirsutism treatment 133, 136–7, 178–9
 impact on HRQoL 56, 57
 indications/recommendations 181
 infertility treatment 147–8, 174–7, 180–1
 clomifene comparison 148, 175, 176
 clomifene with 175–6
 live birth rate 176, 181
 malformations and 178
 multiple pregnancy rates 176
 not recommended by ESHRE/
 ASRM 148, 175, 214
 OHSS prevention 176, 181
 pregnancy complications 177–8, 181
 rationale 174
 trials 147–8, 174–6
 in IVM 189
 mechanism of action 136, 173
 in metabolic syndrome 67, 68
 miscarriage, effect on 148, 177
 orlistat comparison 107
 PCOS management 67, 99
 adolescence 76–7, 78–9
 for premature pubarche 174, 181
 risk/benefit ratio 177
 safety in pregnancy 148, 178
 weight loss 180
- Mexican American women, PCOS 28, 29
- minoxidil 137
- miscarriage 55
 metformin effect 148, 177
 rates, IVF *vs* IVM 190
- morbidity 5
- morphology, polycystic ovaries 1, 3–4, 9
- multicystic ovaries, ultrasound 6
- multidisciplinary approach 213
- muscle sympathetic nervous activity (MSNA)
 198, 204
- Muslim women, infertility concerns 54–5
- myocardial infarction 85
- naloxone 198, 199
- naltrexone 198, 199
- National Institute for Health and Clinical Excellence (NICE), bariatric surgery 110
- National Institutes of Health (NIH), PCOS diagnosis 117
- nerve growth factor (NGF) 196, 200, 204
- neuroendocrine defects, PCOS due to 198
- neuropeptides, released during acupuncture 196, 197–8
- neuropeptide Y (NPY) 204

- non-alcoholic steatohepatitis 66–7
- nutritional deficiencies, after bariatric surgery 112
- obesity, and PCOS 1–2, 4, 9, 14
 central 33, 64, 74
 metformin effect 180
 children, PCOS prevalence 18
 as chronic inflammatory state 65
 complications 89
 ethnic variations 32–5, 36
 Asian women 32–4
 non-Asian women 34–5
 impact on HRQoL 52–4, 58
 management 94, 105–15
 acupuncture 203
 drug therapy 99, 106–9
 lifestyle management 98–9, 105–6
 long-term 98
 PCOS improvement 97–8
 surgery *see* bariatric surgery
 WHO recommendations 94
 see also weight loss
 non-alcoholic fatty liver disease risk 66
 outcome of FSH therapy and 160
 pathophysiology of PCOS 94, 96, 105
 PCOS phenotype worsened by 96–7
 prevalence 94–5, 105
 visceral, development 96
 see also overweight
- obstructive sleep apnoea 89
- oestrogen *see* estrogen
- OHSS *see* ovarian hyperstimulation syndrome (OHSS)
- oligomenorrhoea 47, 147, 159
- oocytes
 mature, collection 187
 quality, FSH regulation 157
- oocytes, immature
 aspiration 186–7
 safety aspects 190
 IVM *see in vitro* maturation of oocytes (IVM)
 number collected 187–8
 timing of retrieval 186, 189
- opioids 199
- oral contraceptive pills 195
 acne management 130–1
 in adolescence 75–6, 78
 effect on insulin resistance 75–6
 efficacy, bariatric surgery effect 112
 hirsutism management 135, 137
 venous thromboembolism and 131
- orlistat 99, 106–7
 adverse and beneficial effects 107
- ovarian blood flow, electro-acupuncture effect 204
- ovarian cancer 89
- ovarian dysfunction 4
 single-nucleotide polymorphism for 161
- ovarian failure, laparoscopic ovarian diathermy and 167
- ovarian hyperstimulation syndrome (OHSS)
 clinical features 185
 IVF association 185, 190
 prediction, genetic factors in 161
 prevention 186
 acupuncture use 202
 IVM use 190
 by low-dose gonadotrophins 148
 metformin role 176
 risk factors 185, 190
- ovarian response 153–64
 to anti-estrogen therapy 154–7
 definition 153
 genetic predictors 161–2
 to gonadotrophins 157–60
 individualised treatment 153, 161
 predictors 153–64
- ovarian stimulation 185, 188
 response to *see* ovarian response
 see also clomifene citrate; follicle-stimulating hormone (FSH)
- ovary
 ultrasound appearance *see* ultrasound
 volume, increase 72, 73
 wedge resection 165–6, 200
- overweight
 adolescents 53, 74, 95
 children, PCOS prevalence 18
 impact on HRQoL 52–4, 58
 PCOS pathophysiology 94
 see also obesity, and PCOS
- ovulation
 acupuncture effects on 200–2
 dysfunction 18
 see also anovulation; infertility
 FSH regulation and 157
 induction *see* anovulation, treatment
 weight loss improving 100, 105–6, 143
- p75 neurotrophin receptor (p75^{NTR}) 204
- paeonia 205
- pathogenesis of PCOS 2, 13–23, 199
 early development 14–16, 74–5, 95
 β -endorphin role 198, 199
 genes/genetic factors 16–17
 insulin role 63
 intrauterine environment role 14, 18
- pathophysiology of PCOS 94, 96, 105
- phenotypic variations 25, 33–4
- photoepilation 134
- pioglitazone 107, 137
- Polycystic Ovary Syndrome Questionnaire (PCOSQ) 49, 50, 57
- post-inflammatory hyperpigmentation 128
- precocious pubarche 71, 74
- preconception counselling 133, 213
- prednisolone 129

Cambridge University Press

978-1-906-98541-7 - Current Management of Polycystic Ovary Syndrome

Edited by Adam Balen, Stephen Franks, Roy Homburg and Sean Kehoe

Index

[More information](#)

226 | INDEX

- pregnancy
 - after bariatric surgery 110, 111–12
 - complications
 - after bariatric surgery 112
 - metformin and 177–8
 - continuing, factors predicting, after FSH therapy 159
 - metformin during 178
 - multiple
 - clomifene association 176–7
 - IVF association 185
 - multiple, prevention 148
 - metformin effect 176
 - prolonged embryo culture 185
- pregnancy rates
 - aromatase inhibitors 146–7
 - clomifene citrate 145, 155, 176–7
 - FSH therapy 155, 168, 169
 - hMG therapy 168, 169
 - IVF *vs* IVM 190
 - IVM 187, 190
 - laparoscopic ovarian diathermy 166, 168, 169
 - metformin effect 67
 - wedge resection of ovary 166
- prevalence of PCOS 4, 13, 38–9, 47
 - ethnic groups 40
 - see also* epidemiology of PCOS
- progesterone
 - luteal support, *in vitro* maturation (IVM) 187
 - measurement, anovulation diagnosis 121, 122
- progestin, in oral contraceptives, acne treatment 130
- prolactin, normal range 3
- Propionibacterium acnes* 127
- psychological distress 39, 47, 196, 213
 - ethnic variations 52
 - impact of PCOS treatment on 56
- puberty
 - hormonal changes 73, 95
 - hyperinsulinaemia of 16
 - insulin resistance increase 16
 - management of PCOS 71–83
 - PCOS manifestation 15, 71
 - see also* adolescents, PCOS in
- quality of life, in PCOS 47–61
 - body mass index impact 53
 - ethnic differences 39
 - lifestyle change effect in adolescents 74
- questionnaires, HRQoL *see* health-related quality of life (HRQoL)
- race 25–6
 - see also* ethnic variations, of PCOS expression
- 5 α -reductase 35, 126, 130
 - inhibition by finasteride 133, 137
- research, consensus views 214–15
- retinoids 128, 133
- rosiglitazone 137, 179
- Rotterdam criteria 4, 6, 13
 - concerns over 13–14
 - criteria listed 13, 71
 - follicle number and ovarian volume 7
 - LH:FSH ratio discarded 121
 - PCOS diagnosis in adolescence 71–4
- Roux-en-Y gastric bypass 110
- Sairei-to 206
- sebaceous glands, excess androgen effect 125
- sebocytes, proliferation 125
- seborrhoea 127, 130
- sebum, increased production 125, 127
 - reduced by androgen receptor blockers 132, 133
 - reduced by co-cyprindiol 130–1
 - reduced by oral contraceptives 130
- self-image, poor 53, 55, 58, 89
- serine phosphorylation 96
- sex hormone-binding globulin (SHBG) 126
 - free androgen index calculation 87, 120
 - increased by estrogen 130
 - normal range 3
 - in obesity and PCOS 96
 - orlistat effect 107
 - PCOS pathogenesis 14
 - in puberty/adolescence 73, 78
 - in South Asian women 33
- sexual functioning, in PCOS 55
- SF-36 50–1, 56
- Shakuyaku-Kanzo-To 205–6
- sibutramine 99, 107–9
 - adverse/beneficial effects 108
- single-nucleotide polymorphisms (SNPs) 161–2
- South Asian people 26, 28, 29, 30
 - UK-based 28, 32
- spearmint 206
- spironolactone 79
 - acne treatment 132
 - in adolescence 77
 - adverse effects 132
 - hirsutism management 135–6
- Sri Lankan women, PCOS phenotypes 33–4, 37, 39
 - PCOS prevalence 39
- Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) 207
- steatohepatitis, non-alcoholic 66–7
- steroid hormones, metabolism, adipocyte role 96
- stress, HPA axis and cortisol 198
- stromal:ovarian area ratio 8, 9
- stromal hypertrophy 8
- suicide attempts 52, 196
- superovulation 167

Cambridge University Press

978-1-906-98541-7 - Current Management of Polycystic Ovary Syndrome

Edited by Adam Balen, Stephen Franks, Roy Homburg and Sean Kehoe

Index

[More information](#)

- surgical management, of anovulatory infertility
 - 165–72
 - key points and practice points 170
 - LOD *see* laparoscopic ovarian diathermy (LOD)
 - transvaginal hydrolaparoscopy 169
 - wedge resection of ovary 165–6
- sympathetic nervous system
 - acupuncture effects on 198, 204
 - β -endorphin effect 198
 - increased activity in PCOS 200
- symptoms/signs of PCOS 1, 2
 - in adolescence 73–4
 - factors affecting 1
 - heterogeneity 1, 9, 13, 14, 117
- Taiwanese women, hyperandrogenism 35, 37–8
- testosterone
 - accumulation in adipose tissue 96
 - elevated in PCOS 5, 95, 126
 - adolescence 71, 78
 - high sympathetic nerve activity and 200
 - hirsutism and 35
 - hyperandrogenism diagnosis by 120
 - immunoassays, and bias 120, 121
 - measurement 120, 121
 - time of day 120, 122
 - menstrual cycle phase effects on levels 120
 - normal range 3, 122
 - PCOS development 95
 - PCOS diagnosis 8
 - physiological variations (women) 121
 - in prediction of response to FSH 159
 - in puberty/adolescence (levels) 71, 73, 78
 - reduced by herbal therapy 205
 - reference range 122
- Thai women, PCOS 33
- theca cell steroidogenesis 18
 - abnormalities 16–17
- thiazolidinediones 173
 - contraindication in pregnancy 77
 - diabetes prevention in PCOS 179
 - for infertility 177
 - PCOS management, adolescence 77
- thromboembolism 76
- thyroid dysfunction 8–9
- thyroid-stimulating hormone (TSH) 3
- traditional Chinese medicine (TCM) 195
- transforming growth factor-beta (TGF β) 17
- transvaginal hydrolaparoscopy 169
- treatment of PCOS 67–8, 93, 196
 - of acne and hirsutism *see* acne; hirsutism
 - aims 93, 196
 - impact on HRQoL 55–7
 - improved by obesity treatment 97–8
 - of infertility *see* anovulation
 - lifestyle modification *see* lifestyle management
 - in puberty and adolescence *see* adolescents
 - weight loss *see* weight loss
- triglycerides
 - cyproterone acetate increasing 76
 - metabolic syndrome diagnosis 64, 87
 - sibutramine increasing 108
- troglitazone 50, 179
- ultrasound 2–3, 4, 6, 9
 - in adolescence 72–3, 78
 - multicystic/polycystic ovaries 6
 - rectal 72
 - stromal echogenicity 7
 - three-dimensional 8, 9
 - transabdominal 6, 72, 78
 - transvaginal 6–8, 72, 186
- uncoupling protein 2 (UCP2) 203
- Unkei-to 205
- USA
 - ethnic groups 26
 - PCOS prevalence 34
- vellus hair 125
- venous thromboembolism 131
- very low calorie diets 106
- Vitex agnus-castus* 205
- waist circumference
 - ethnic variations 33, 34
 - HDL cholesterol and 87
 - metabolic syndrome and 33, 64, 86, 87
- weight gain, early, PCOS development 95
- weight loss
 - acupuncture effect 203
 - adolescents 75
 - bariatric surgery 109
 - difficulties 53
 - extent, and effect on hormones 106
 - hirsutism management 134
 - as key aim of treatment 94
 - metformin action 180
 - obesity treatment 98, 106
 - ovulation rate improvement 100, 105–6, 143
 - PCOS treatment 67, 98, 213–14
 - sibutramine 107–8
 - see also* obesity, and PCOS
- white peony 205
- WHQOL-BREF 51, 56
- Yasmin® 131–2
- YAZ® 132